The combination of TAS-118 and oxaliplatin led to significantly greater survival compared with the S-1 and cisplatin combination in patients with metastatic or recurrent HER2-negative gastric cancer, the phase III SOLAR* study showed.
Reducing the dose of regorafenib did little to affect the overall tolerability of the drug in patients with metastatic colorectal cancer (mCRC), according to the phase II REARRANGE* trial presented at ESMO GI 2019.
The survival benefit with ramucirumab was consistent in patients with advanced hepatocellular carcinoma (HCC) and high alpha-fetoprotein (AFP) levels regardless of whether they were previously treated with transarterial chemoembolization (TACE), a post hoc analysis of pooled data from the REACH/REACH-2 studies shows.
Augmenting the triple chemotherapeutic regimen FOLFOXIRI* with bevacizumab demonstrated favourable efficacy regardless of age and gender in patients with unresectable metastatic colorectal cancer (mCRC), according to data presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2019.
Adding bevacizumab to trifluridine/tipiracil (FTD/TPI) significantly improves progression-free survival (PFS) and overall survival (OS) compared with FTD/TPI in patients with chemorefractory metastatic colorectal cancer (mCRC), according to a study presented at ESMO GI 2019.
A triple-drug combination therapy comprising encorafenib, binimetinib, and cetuximab significantly improved survival compared with the current standard of care chemotherapy in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who had failed one or two prior treatments, according to the BEACON CRC study presented at the recent ESMO World Congress on Gastrointestinal Cancer (ESMO GI).
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Macrolide antibiotics are derived from the Streptomycesspecies. These contain either 14-membered (erythromycin [ERM],clarithromycin [CAM], roxithromycin [RXM]), 15-membered(azithromycin [AZM]) or 16-membered (spiramycin, josamycin,midecamycin) macrocyclic lactone rings. They inhibit proteinsynthesis by reversibly binding to the 23S ribosomal RNA (rRNA)in the 50s subunit of the bacterial ribosome. Traditionally,macrolides are used as first-line agents in respiratory, skin,soft tissue, and urogenital infections, and they are also activeagainst gram-positive cocci and atypical pathogens.
Nonsmall cell lung cancer (NSCLC) patients harbouring sensitive EGFR mutations may fare well with the third-generation tyrosine kinase inhibitor osimertinib as an upfront therapy, with the results of a network meta-analysis showing that the drug tops other currently available options in terms of progression-free survival and tolerability.
Pneumonia is a common infection– affecting around 3,200 people inSingapore in 2016 – making it the thirdmost common cause of hospitalisation inthe country. Its common complications,especially with delayed or inappropriatetreatment, include bacteraemia andseptic shock, lung abscesses, pleuraleffusions, empyema, pleurisy, respiratoryfailure and renal failure.